Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Reuters

Published November 17, 2026 · Updated November 18, 2026

Helus psychedelic depression drug succeeds in trial amid safety scrutiny - Reuters

Read the full story at Reuters

Press Releases · Subscribe. Helus psychedelic depression drug succeeds in trial amid safety scrutiny ... Nov 16 (Reuters) - Helus Pharma (HELP.NLB) ,.

Surfaced by 3 Google Alerts

  • Psychedelic press release
  • Magic mushrooms
  • Psychedelic crime